Immunomodulatory properties of a viral homolog of human interleukin-10 expressed by human cytomegalovirus during the latent phase of infection.

Human cytomegalovirus (HCMV) establishes a latent infection in hematopoietic cells, from which it can reactivate to cause significant disease in immunocompromised individuals. HCMV expresses a functional homolog of the immunosuppressive cytokine interleukin-10 (termed cmvIL-10), and alternate splicing of the cmvIL-10 transcript results in expression of a latency-associated cmvIL-10 transcript (LAcmvIL-10). To determine whether LAcmvIL-10 encodes immunosuppressive functions, recombinant LAcmvIL-10 protein was generated, and its impact on major histocompatibility complex class II (MHC-II) expression was examined on granulocyte macrophage progenitor cells (GM-Ps) and monocytes. LAcmvIL-10 (and cmvIL-10) downregulated MHC-II on the surfaces of both cell types. This downregulation was associated with a decrease in total MHC-II protein and transcription of components of the MHC-II biosynthesis pathway. Unlike cmvIL-10, LAcmvIL-10 did not trigger phosphorylation of Stat3, and its ability to downregulate MHC-II was not blocked by neutralizing antibodies to the human IL-10 receptor, suggesting that LAcmvIL-10 either does not engage the cellular IL-10 receptor or utilizes it in a different manner from cmvIL-10. The impact of LAcmvIL-10 on dendritic cell (DC) maturation was also assessed. In contrast to cmvIL-10, LAcmvIL-10 did not inhibit the expression of costimulatory molecules CD40, CD80, and CD86 and the maturation marker CD83 on DCs, nor did it inhibit proinflammatory cytokines (IL-1alpha, IL-1beta, IL-6 and tumor necrosis factor alpha). Thus, LAcmvIL-10 retains some, but not all, of the immunosuppressive functions of cmvIL-10. As GM-Ps and monocytes support latent infection, expression of LAcmvIL-10 may enable HCMV to avoid immune recognition and clearance during latency.

Risk of altitude exposure in sickle cell disease.

The risk of altitude-induced hypoxemia causing painful crisis was determined in a group of 45 predominantly adult patients with sickle cell disease. The patients were divided into two groups: those with hemoglobin (Hb) SS and those with Hb SC or Hb S beta-thalassemia. Altitude exposures were divided into airplane travel and mountain visits, and the latter subdivided into stays at 4,400 or 6,320 ft. The average risk of crisis was higher for both groups while in the mountains (37.9 percent and 56.6 percent, respectively) than it was during airplane travel (10.8 percent and 13.5 percent, respectively). The latter group had more splenic crises than the former group and also had a greater risk at 6,320 ft (65.9 percent) than at 4,400 ft (20.0 percent). Patients with sickle cell disease are at high risk of crisis in the mountains, and we advise those with intact spleens to breathe supplemental oxygen during air travel.